Supplement 1

Eligibility criteria

1) Adult outpatients with mild or moderate stable asthma (GINA treatment step 2 or 3)
2) Patients who provided written, informed consent after being given and understanding a detailed explanation of the study
3) Patients with asthma control questionnaire scores less than 0.75
4) Patients who have been using medium dose of dry powder type inhaled corticosteroid and long-acting beta 2 agonist (ICS/LABA) for treatment for more than 3 months before enrolment.
5) No histories of formoterol/fluticasone combination (FFC) as pMDI devise use and vilanterol/fluticasone combination (VFC) as Ellipta device use.
6) Patients who retained a good level of drug adherence to prior drug therapy after checking inhalation technique
7) Patients who could inhale adequately every time with no medical assistance.
8) Patients who accepted inhaling FFC pMDI without using an inhalation spacer.